Randomised double-blind,placebo-controlled trial of the effects of the ‘party pills’ BZP/TFMPP alone and in combination with alcohol

Abstract

The objective of this study was to determine the clinical effects of party pills containing benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) when taken alone and in combination with alcohol. The study was a randomised, double-blind, placebo-controlled trial conducted in a hospital-based clinic in Wellington, New Zealand. Thirty-five volunteers who had previously used party pills containing BZP were included in this trial. Participants received one of the following four treatments: 300 mg/74 mg BZP/TFMPP and placebo, 300 mg/74 mg BZP/TFMPP and 57.6 g (6 units) alcohol, placebo and 57.6 g (6 units) alcohol and double placebo. The primary outcome variable was a measure of driving performance, the standard deviation of lateral position (SDLP) measured at 6.5 h. Secondary measures included adverse events, cardiovascular effects, psychological function and delayed effects on sleep. The study was stopped early, after 35 of the planned 64 subjects had undertaken testing, because of severe adverse events that occurred in four of 10 BZP/TFMPP-only subjects, three of seven combined BZP/TFMPP and alcohol subjects, none of the 6 placebo subjects, and none of the 12 alcohol-only subjects. The overall rate of severe adverse events (defined as causing considerable interference with usual activity and/or rated by subject as severe) in those receiving BZP/TFMPP was seven of 17 (41.2%, 95% CI 18.4—67.1). The severe events included agitation, anxiety, hallucinations, vomiting, insomnia and migraine. BZP/TFMPP significantly improved the driving performance, decreasing SDLP at −4.2 cm (95% CI −6.8 to −1.6, P = 0.002). The effect of alcohol was to increase SDLP: 2.3 cm (95% CI −0.3 to 4.9, P = 0.08). BZP/TFMPP also resulted in increased heart rate and blood pressure and in difficulty in getting to sleep. BZP/TFMPP alone or with alcohol carries a significant risk of severe adverse events when taken in similar doses to those recommended by manufacturers.

Keywords

adverse events alcohol benzylpiperazine driving performance party pills trifluromethylphenylpiperazine

Get full access to this article

View all access options for this article.

References

Alansari, M. , Hamilton, D. ( 2006) Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. N Z Med J 119: U1959.

Allen, R. , Rosenthal, T. , Aponso, B. ( 1998) Low-cost simulation for safety research, prototyping and training. Hawthorne, California : Systems Technology, Inc. http://www.systemstech.com/component/option,com_docman/task,cat_view/gid,31/Itemid,72/ (accessed May 2008).

American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, fourth ed, text revision . Washington, DC: American Psychiatric Association.

Baumann, M. , Clark, R. , Budzynski, A. , Partilla, J. , Blough, B. , Rothman, R. ( 2005) N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’) . Neuropsychopharmacol 30: 550-560.

Boutrel, B. , Koob, G. ( 2004) What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 27: 1181-1194.

Brookhuis, K. , de Waard, D. ( 1994) Measuring driving performance by car-following in traffic . Ergonomics 37: 427-434.

Brookhuis, K. ( 1998) How to measure driving ability under the influence of alcohol and drugs, and why. Hum Psychopharmacol 13: S64-S69.

Bye, C. , Munro-Faure, A. , Peck, A. , Young, P. ( 1973) A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 6: 163-169.

Campbell, H. , Cline, W. , Evans, M. , Lloyd, J. , Peck, A. ( 1973) Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol 6: 170-176.

10.

Conners, C. ( 2004) Conners’ Continuous Performance Test for Windows (CPT II) Technical Guide and Software Manual. Toronto: Multi-Health Systems Inc.

11.

Fantegrossi, W. , Winger, G. , Woods, J. , Woolverton, W. , Coop, A. ( 2005) Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenyl-piperazine in rhesus monkeys . Drug Alcohol Depend 77: 161-168.

12.

Gee, P. , Fountain, J. ( 2007) Party on? BZP party pills in New Zealand. N Z Med J 120: U2422.

13.

Gee, P. , Richardson, S. , Woltersdorf, W. , Moore, G. ( 2005) Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N Z Med J 118: U1784.

14.

Gossop, M. ( 2006) Classification of illegal and harmful drugs. BMJ 333: 272-273.

15.

Gustavsen, I. , Morland, J. , Bramness, J. ( 2006) Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drug drivers. Accid Anal Prev 38: 490-495.

16.

Harnett, MA ( 2007) Piperazine-based party drugs: case series of 73 poisonings. International Congress of Poisons Centres and Clinical Toxicologists . Clin Toxicol 45: (abstract XXVII).

17.

Hoddes, E. , Zarcone, V. , Smythe, H. , Phillips, R. , Dement, W. ( 1973) Quantification of sleepiness: a new approach. Psychophysiology 10: 431-436.

18.

Lenne, MG , Dietze, P. , Rumbold, ER , Redman, JR , Triggs, TJ ( 2003) The effects of the opioid pharmacotherapies methadone, LAM and buprenorphine, alone and in combination with alcohol, on simulated driving. Drug Alcohol Depend 72: 271-278.

19.

Magyar, K. , Fekete, M. , Tekes, K. , Torok, T. ( 1986) The action of trelibet, a new antidepressive agent on [3H]noradrenaline release from rabbit pulmonary artery. Eur J Pharmacol 130: 219-227.

20.

McNair, D. , Heuchert, J. ( 2005) Profile of Mood States Technical Update. Toronto, Canada: Multi-Health Systems Inc.

21.

Mendelson, J. , Jones, R. , Upton, R. , Jacob, P. ( 1995) Methamphetamine and ethanol interactions in humans . Clin Pharmacol Ther 57: 559-568.

22.

Nicholson, TC ( 2006) Prevalence of use, epidemiology and toxicity of ‘herbal party pills’ among those presenting to the emergency department . Emerg Med Australas 18: 180-184.

23.

Nutt, D. ( 1996) Addiction: brain mechanisms and their treatment implications . Lancet 347: 31-38.

24.

Parrott, A. , Hindmarch, I. ( 1980) The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacol 71: 173-179.

25.

Perez-Reyes, M. , White, W. , McDonald, S. , Hicks, R. ( 1992) Interaction between ethanol and dextroamphetamine: effects on psychomotor performance. Alcohol Clin Exp Res 16: 75-81.

26.

Philip, P. , Sagaspe, P. , Moore, N. , Taillard, J. , Charles, A. , Guilleminault, C. , et al. (2005) Fatigue, sleep restriction and driving performance . Accid Anal Prev 37: 473-478.

27.

Tekes, K. , Tothfalusi, L. , Malomvolgyi, B. , Herman, F. , Magyar, K. ( 1987) Studies on the biochemical mode of action of EGYT-475, a new antidepressant. Pol J Pharmacol Pharm 39: 203-211.

28.

University of Kentucky Clinical Research Organisation ( 2007) Conducting Clinical Trials A-Z. http://www.mc.uky.edu/ukcro/manual/coordination_and_operations_page.htm (accessed May 2008).

29.

Vince, G. ( 2006) Mind-altering drugs: does legal mean safe? New Sci 2571: 40-45.

30.

Vollenweider, F. , Leichti, M. , Gamma, A. , Greer, G. , Geyer, M. ( 2002) Acute psychological and neurophysiological effects of MDMA in humans. J Psychoactive Drugs 34: 171-185.

31.

Weschler, D. ( 1981) Wechsler Adult Intelligence Scale - Revised. New York: The Psychological Corporation .

32.

Wilkins, C. , Girling, M. , Sweetsur, P. , Huckle, T. , Huakau, J. ( 2006) Legal Party Pill Use in New Zealand: Prevalence of Use, Availability, Health Harms and "Gateway Effects" of Benzylpiperazine (BZP) and Trifluorophenylmethylpiperazine (TFMPP). Auckland : Centre of Social and Health Outcomes Research and Evaluation (SHORE), Massey University.

33.

Williamson, AM , Feyer, A. ( 2000) Moderate sleep deprivation produces impairments in cognitive and motor performance equivalent to legally prescribed levels of alcohol intoxication . Occup Environ Med 57: 649-655.

34.

Wood, DM , Dargan, PI , Button, J. , Holt, DW , Ovaska, H. , Ramsey, J. , et al. (2007) Collapse, reported seizure - and an unexpected pill. Lancet 369: 1490.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.16 MB